Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Fortress Biotech (FBIO) over the last 11 years, with Q3 2025 value amounting to $18.0 million.

  • Fortress Biotech's Receivables - Net rose 6852.22% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year increase of 6852.22%. This contributed to the annual value of $10.2 million for FY2024, which is 3278.81% down from last year.
  • Latest data reveals that Fortress Biotech reported Receivables - Net of $18.0 million as of Q3 2025, which was up 6852.22% from $15.6 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Receivables - Net ranged from a high of $31.7 million in Q3 2021 and a low of $8.0 million during Q3 2023
  • Its 5-year average for Receivables - Net is $20.0 million, with a median of $18.7 million in 2021.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 25998.15% in 2021, then tumbled by 7200.08% in 2023.
  • Over the past 5 years, Fortress Biotech's Receivables - Net (Quarter) stood at $23.1 million in 2021, then increased by 22.05% to $28.2 million in 2022, then tumbled by 46.04% to $15.2 million in 2023, then plummeted by 32.79% to $10.2 million in 2024, then skyrocketed by 75.77% to $18.0 million in 2025.
  • Its last three reported values are $18.0 million in Q3 2025, $15.6 million for Q2 2025, and $18.0 million during Q1 2025.